‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose
Eli Lilly has announced a new gene-editing therapy, VERVE-102, which can reduce LDL cholesterol by up to 62% with a single dose. The treatment works by turning off the PCSK9 gene, which is responsible for regulating cholesterol levels in the liver. Preliminary results from a small trial show promising outcomes, with no serious adverse effects reported.
- ▪VERVE-102 can lower LDL cholesterol by up to 62% with just one infusion.
- ▪The treatment has shown lasting effects, with results still evident in some participants 18 months later.
- ▪A Phase 2 clinical study of VERVE-102 is expected to begin by the end of the year.
New York Post files mainly under news. We currently carry 11,009 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | New York Post |
| Canonical URL | https://nypost.com/2026/05/26/health/revolutionary-single-dose-treatment-cuts-cholesterol-by-62/ |
| Publication time | Tue, 26 May 2026 14:29:29 -0400 |
| Retrieval time | 2026-05-26T18:32:53.545Z |
| Last seen | 2026-05-26T18:32:53.545Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | go0OWpFtPR-k |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Health ‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose By Rachel Sacks Published May 26, 2026, 2:29 p.m. ET See more of our coverage in your search results. Add The New York Post on Google One and done? Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up to 62% with a single infusion. Not only was the experimental treatment successful, but the results were still apparent in some participants 18 months after they received the dose. VERVE-102 may be a revolutionary treatment for bad cholesterol before it leads to heart disease.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
